The Medicines Company (MDCO) 25.39 $MDCO
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines
PR Newswire - Fri Dec 12, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Akorn Inc. (NASDAQ: AKRX), and The Medicines Company (NASDAQ: MDCO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 11, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,596.34, up 0.36% and the NASDAQ Composite closed at 4,708.16, up 0.52%. The S&P 500 finished the session 0.45% higher at 2,035.33. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 25.39 (-0.19), AKRX: 41.24 (+0.38), MRK: 57.72 (-1.62), PFE: 30.95 (-0.70), ABBV: 65.27 (-1.76)
Alnylam earns milestone on start of Phase 1 hypercholesterolemia trial
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 8:06AM CST
ALNY: 100.45 (+0.23), MDCO: 25.39 (-0.19)
Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
Business Wire - Thu Dec 11, 7:01AM CST
--- Companies Expect to Present Initial Clinical Results in Mid-2015 -
ALNY: 100.45 (+0.23), MDCO: 25.39 (-0.19)
The Medicines Company to Participate in Oppenheimer 25th Annual Healthcare Conference
Business Wire - Mon Dec 08, 9:15AM CST
The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference in New York, NY on Wednesday, December 10th at 9:10 AM EST.
MDCO: 25.39 (-0.19)
Upgrade Alert for Medicines Co (MDCO)
Comtex SmarTrend(R) - Thu Nov 20, 7:04AM CST
Medicines Co (NASDAQ:MDCO) was upgraded from Neutral to Outperform at Credit Suisse today. The stock closed yesterday at $24.99 on volume of 419,000 shares, below average daily volume of 948,000. The Medicines Company develops products that improve specialized care. The Company markets Angiomax, an anticoagulant approved in the United States and other countries for use in patients undergoing coronary angioplasty procedures.
MDCO: 25.39 (-0.19)
The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters and Was Well-Tolerated in Healthy and Coronary Artery Disease (CAD) Patients
Business Wire - Sun Nov 16, 9:30AM CST
The Medicines Company (NASDAQ:MDCO) today presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association's Annual Scientific Sessions in Chicago.
MDCO: 25.39 (-0.19)
The Medicines Company to Present New Data on Investigational Lipid-Modifying Agent MDCO-216 and Investigational Antiplatelet Agent Cangrelor at 2014 American Heart Association (AHA) Annual Scientific Sessions in Chicago
Business Wire - Fri Nov 14, 9:32AM CST
The Medicines Company (NASDAQ:MDCO) will present new data from studies involving the investigational lipid-modifying agent MDCO-216 and investigational intravenous antiplatelet agent cangrelor during the annual American Heart Association (AHA) Scientific Sessions in Chicago, November 15-19. The oral presentations and abstracts involve clinical data and analyses from two core areas of cardiovascular medicine for the Company: lipid-modifying therapies and acute cardiovascular care.
MDCO: 25.39 (-0.19)
The Medicines Company to Participate in Credit Suisse Healthcare Conference
Business Wire - Tue Nov 11, 10:07AM CST
The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Credit Suisse Healthcare Conference in Phoenix, AZ on Wednesday, November 12th at 1:00 PM Mountain Time / 3:00 PM Eastern Time.
MDCO: 25.39 (-0.19)
Health Economic Data on The Medicines Company's Infectious Disease and Cardiology Portfolios to be Presented at the 17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Business Wire - Fri Nov 07, 2:00PM CST
The Medicines Company (NASDAQ:MDCO) today announced that data from two health economics analyses will be presented at the 17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) being held in Amsterdam, November 8-12. The abstracts involve analyses from two core areas of hospital focus for The Medicines Company: serious infectious disease care and acute cardiovascular care.
MDCO: 25.39 (-0.19)
Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST
ALNY: 100.45 (+0.23), MDCO: 25.39 (-0.19), SNY: 45.16 (-1.05)
The Medicines Company Announces First Patient Enrollment in Phase 3 Studies of CARBAVANCE(TM) in Development for the Treatment of Serious Bacterial Infections Due to Gram-Negative Bacteria
Business Wire - Wed Nov 05, 5:30AM CST
The Medicines Company (NASDAQ:MDCO) today announced enrollment of the first patient in its Phase 3 clinical trial program for CARBAVANCE(TM) (meropenem/RPX7009), an investigational intravenous antibiotic under development for the treatment of serious bacterial infections due to gram-negative bacteria, particularly KPC (Klebsiella pneumoniae carbapenemase)-producing carbapenem-resistant Enterobacteriaceae (CRE).
MDCO: 25.39 (-0.19)
Update to The Medicines Company Investor & Analyst Day on November 5
Business Wire - Tue Nov 04, 3:33PM CST
As previously announced, The Medicines Company (NASDAQ:MDCO) will host an Investor & Analyst Day on Wednesday, November 5, 2014 at the Roosevelt Hotel in New York. The Investor and Analyst Day presentations will start at 8:25 am and go to 12:30 pm Eastern Time. Breakfast will be served from 8:00 am to 8:25 am. MDCO business and science leaders, with invited experts, will provide a comprehensive overview of the Company's business and strategies for growth at what promises to be a highly informative event.
MDCO: 25.39 (-0.19)
The Medicines Company to Webcast Investor & Analyst Day on November 5
Business Wire - Thu Oct 30, 3:03PM CDT
The Medicines Company (NASDAQ: MDCO) has scheduled a webcast of its upcoming Investor & Analyst Day on Wednesday, November 5, 2014, from 8:00 am to 12:00 pm Eastern Time. MDCO business and science leaders, with invited experts, will provide a comprehensive overview of the Company's business and strategies for growth at what promises to be a highly informative event.
MDCO: 25.39 (-0.19)
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 344.49 (+2.16), CBST: 96.31 (+0.04), MDCO: 25.39 (-0.19), SRPT: 13.97 (-0.33), ALXN: 186.90 (-4.72), AMGN: 164.53 (-1.55), CELG: 114.49 (-2.25)
The Medicines Company (MDCO) Jumps: Stock Gains 16.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:25AM CDT
The Medicines Company (MDCO) was a big mover last session, with shares rising nearly 17% on the day.
MDVN: 106.86 (-1.16), BIIB: 344.49 (+2.16), MDCO: 25.39 (-0.19), ILMN: 184.30 (-2.53)
The Medicines Co.'s Angiomax Gets Favorable Court Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:31PM CDT
The Medicines Co. (MDCO) announced that the U.S. District Court for the Northern District of Illinois has ruled in its favor in a patent infringement lawsuit against Mylan.
IPXL: 31.16 (-0.74), ACT: 259.00 (-4.00), MDCO: 25.39 (-0.19), MYL: 53.32 (-1.39)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:46AM CDT
RGSE: 0.60 (+0.02), AMKR: 6.31 (-0.14), VTAE: 22.01 (+0.30), ASTI: 1.20 (-0.03), CLF: 6.74 (-0.20), LMNX: 17.94 (-0.29), IDTI: 19.55 (+0.37), HNR: 1.79 (-0.05), VDSI: 26.92 (-0.86), DCO: 24.73 (-0.33), MDCO: 25.39 (-0.19), SCYX: 10.16 (+0.33), VGGL: 3.30 (-0.09), RCPT: 120.08 (-1.38), IBIO: 0.69 (unch), SNY: 45.16 (-1.05), TWTR: 37.10 (+0.40), DPW: 1.27 (-0.05), MERU: 3.73 (+0.05), SANM: 23.67 (-0.65)
The Medicines Company Announces Presentation of Investigational Hemostatic Agent RAPLIXA(TM) (fibrin sealant) Phase III FINISH-3 Trial Results at the 2014 Clinical Conference of the American College of Surgeons
Business Wire - Tue Oct 28, 10:30AM CDT
The Medicines Company (NASDAQ: MDCO) today announced the presentation of the results of the pivotal Phase III clinical trial of the investigational hemostatic agent RAPLIXA(TM) (fibrin sealant), formerly known as Fibrocaps, at the 100th Clinical Congress of the American College of Surgeons in San Francisco, CA. As previously reported, the Phase III trial, FINISH-3, which studied a total of 719 patients, met all primary and secondary hemostasis efficacy endpoints in four distinct surgical indications of spinal surgery, hepatic resection, vascular surgery and soft tissue dissection. RAPLIXA, currently under regulatory review with the U.S. Food and Drug Administration and the European Medicines Agency, is a dry powder topical formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery.
MDCO: 25.39 (-0.19)
Medicines Co. prevails in patent challenge from Mylan
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 8:43AM CDT
MDCO: 25.39 (-0.19), MYL: 53.32 (-1.39)
Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
Business Wire - Tue Oct 28, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on the world's leading acute/intensive care hospitals, announced today that Alnylam has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia. ALN-PCSsc is a subcutaneously administered RNAi therapeutic targeting the gene proprotein convertase subtilisin/kexin type 9 (PCSK9), a target validated by human genetics that is involved in the metabolism of low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Per the filed CTA, the Phase 1 trial of ALN-PCSsc will be conducted in the U.K. as a randomized, single-blind, placebo-controlled, single ascending- and multi-dose study, enrolling up to 76 volunteer subjects with elevated baseline LDL-C (greater-than or equal to 100 mg/dL). Following approval of the CTA, the companies expect to initiate dosing in the Phase 1 trial in late 2014 or early 2015, with initial data expected to be reported in mid-2015.
ALNY: 100.45 (+0.23), MDCO: 25.39 (-0.19)
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines
PR Newswire - Fri Dec 12, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Akorn Inc. (NASDAQ: AKRX), and The Medicines Company (NASDAQ: MDCO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 11, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,596.34, up 0.36% and the NASDAQ Composite closed at 4,708.16, up 0.52%. The S&P 500 finished the session 0.45% higher at 2,035.33. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 25.39 (-0.19), AKRX: 41.24 (+0.38), MRK: 57.72 (-1.62), PFE: 30.95 (-0.70), ABBV: 65.27 (-1.76)
Alnylam earns milestone on start of Phase 1 hypercholesterolemia trial
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 8:06AM CST
ALNY: 100.45 (+0.23), MDCO: 25.39 (-0.19)
Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
Business Wire - Thu Dec 11, 7:01AM CST
--- Companies Expect to Present Initial Clinical Results in Mid-2015 -
ALNY: 100.45 (+0.23), MDCO: 25.39 (-0.19)
The Medicines Company to Participate in Oppenheimer 25th Annual Healthcare Conference
Business Wire - Mon Dec 08, 9:15AM CST
The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference in New York, NY on Wednesday, December 10th at 9:10 AM EST.
MDCO: 25.39 (-0.19)
Upgrade Alert for Medicines Co (MDCO)
Comtex SmarTrend(R) - Thu Nov 20, 7:04AM CST
Medicines Co (NASDAQ:MDCO) was upgraded from Neutral to Outperform at Credit Suisse today. The stock closed yesterday at $24.99 on volume of 419,000 shares, below average daily volume of 948,000. The Medicines Company develops products that improve specialized care. The Company markets Angiomax, an anticoagulant approved in the United States and other countries for use in patients undergoing coronary angioplasty procedures.
MDCO: 25.39 (-0.19)
The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters and Was Well-Tolerated in Healthy and Coronary Artery Disease (CAD) Patients
Business Wire - Sun Nov 16, 9:30AM CST
The Medicines Company (NASDAQ:MDCO) today presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association's Annual Scientific Sessions in Chicago.
MDCO: 25.39 (-0.19)
The Medicines Company to Present New Data on Investigational Lipid-Modifying Agent MDCO-216 and Investigational Antiplatelet Agent Cangrelor at 2014 American Heart Association (AHA) Annual Scientific Sessions in Chicago
Business Wire - Fri Nov 14, 9:32AM CST
The Medicines Company (NASDAQ:MDCO) will present new data from studies involving the investigational lipid-modifying agent MDCO-216 and investigational intravenous antiplatelet agent cangrelor during the annual American Heart Association (AHA) Scientific Sessions in Chicago, November 15-19. The oral presentations and abstracts involve clinical data and analyses from two core areas of cardiovascular medicine for the Company: lipid-modifying therapies and acute cardiovascular care.
MDCO: 25.39 (-0.19)
The Medicines Company to Participate in Credit Suisse Healthcare Conference
Business Wire - Tue Nov 11, 10:07AM CST
The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Credit Suisse Healthcare Conference in Phoenix, AZ on Wednesday, November 12th at 1:00 PM Mountain Time / 3:00 PM Eastern Time.
MDCO: 25.39 (-0.19)
Health Economic Data on The Medicines Company's Infectious Disease and Cardiology Portfolios to be Presented at the 17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Business Wire - Fri Nov 07, 2:00PM CST
The Medicines Company (NASDAQ:MDCO) today announced that data from two health economics analyses will be presented at the 17th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) being held in Amsterdam, November 8-12. The abstracts involve analyses from two core areas of hospital focus for The Medicines Company: serious infectious disease care and acute cardiovascular care.
MDCO: 25.39 (-0.19)
Alnylam Pharmaceuticals Staying Ridiculously Busy
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 07, 10:25AM CST
ALNY: 100.45 (+0.23), MDCO: 25.39 (-0.19), SNY: 45.16 (-1.05)
The Medicines Company Announces First Patient Enrollment in Phase 3 Studies of CARBAVANCE(TM) in Development for the Treatment of Serious Bacterial Infections Due to Gram-Negative Bacteria
Business Wire - Wed Nov 05, 5:30AM CST
The Medicines Company (NASDAQ:MDCO) today announced enrollment of the first patient in its Phase 3 clinical trial program for CARBAVANCE(TM) (meropenem/RPX7009), an investigational intravenous antibiotic under development for the treatment of serious bacterial infections due to gram-negative bacteria, particularly KPC (Klebsiella pneumoniae carbapenemase)-producing carbapenem-resistant Enterobacteriaceae (CRE).
MDCO: 25.39 (-0.19)
Update to The Medicines Company Investor & Analyst Day on November 5
Business Wire - Tue Nov 04, 3:33PM CST
As previously announced, The Medicines Company (NASDAQ:MDCO) will host an Investor & Analyst Day on Wednesday, November 5, 2014 at the Roosevelt Hotel in New York. The Investor and Analyst Day presentations will start at 8:25 am and go to 12:30 pm Eastern Time. Breakfast will be served from 8:00 am to 8:25 am. MDCO business and science leaders, with invited experts, will provide a comprehensive overview of the Company's business and strategies for growth at what promises to be a highly informative event.
MDCO: 25.39 (-0.19)
The Medicines Company to Webcast Investor & Analyst Day on November 5
Business Wire - Thu Oct 30, 3:03PM CDT
The Medicines Company (NASDAQ: MDCO) has scheduled a webcast of its upcoming Investor & Analyst Day on Wednesday, November 5, 2014, from 8:00 am to 12:00 pm Eastern Time. MDCO business and science leaders, with invited experts, will provide a comprehensive overview of the Company's business and strategies for growth at what promises to be a highly informative event.
MDCO: 25.39 (-0.19)
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 344.49 (+2.16), CBST: 96.31 (+0.04), MDCO: 25.39 (-0.19), SRPT: 13.97 (-0.33), ALXN: 186.90 (-4.72), AMGN: 164.53 (-1.55), CELG: 114.49 (-2.25)
The Medicines Company (MDCO) Jumps: Stock Gains 16.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:25AM CDT
The Medicines Company (MDCO) was a big mover last session, with shares rising nearly 17% on the day.
MDVN: 106.86 (-1.16), BIIB: 344.49 (+2.16), MDCO: 25.39 (-0.19), ILMN: 184.30 (-2.53)
The Medicines Co.'s Angiomax Gets Favorable Court Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:31PM CDT
The Medicines Co. (MDCO) announced that the U.S. District Court for the Northern District of Illinois has ruled in its favor in a patent infringement lawsuit against Mylan.
IPXL: 31.16 (-0.74), ACT: 259.00 (-4.00), MDCO: 25.39 (-0.19), MYL: 53.32 (-1.39)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:46AM CDT
RGSE: 0.60 (+0.02), AMKR: 6.31 (-0.14), VTAE: 22.01 (+0.30), ASTI: 1.20 (-0.03), CLF: 6.74 (-0.20), LMNX: 17.94 (-0.29), IDTI: 19.55 (+0.37), HNR: 1.79 (-0.05), VDSI: 26.92 (-0.86), DCO: 24.73 (-0.33), MDCO: 25.39 (-0.19), SCYX: 10.16 (+0.33), VGGL: 3.30 (-0.09), RCPT: 120.08 (-1.38), IBIO: 0.69 (unch), SNY: 45.16 (-1.05), TWTR: 37.10 (+0.40), DPW: 1.27 (-0.05), MERU: 3.73 (+0.05), SANM: 23.67 (-0.65)
The Medicines Company Announces Presentation of Investigational Hemostatic Agent RAPLIXA(TM) (fibrin sealant) Phase III FINISH-3 Trial Results at the 2014 Clinical Conference of the American College of Surgeons
Business Wire - Tue Oct 28, 10:30AM CDT
The Medicines Company (NASDAQ: MDCO) today announced the presentation of the results of the pivotal Phase III clinical trial of the investigational hemostatic agent RAPLIXA(TM) (fibrin sealant), formerly known as Fibrocaps, at the 100th Clinical Congress of the American College of Surgeons in San Francisco, CA. As previously reported, the Phase III trial, FINISH-3, which studied a total of 719 patients, met all primary and secondary hemostasis efficacy endpoints in four distinct surgical indications of spinal surgery, hepatic resection, vascular surgery and soft tissue dissection. RAPLIXA, currently under regulatory review with the U.S. Food and Drug Administration and the European Medicines Agency, is a dry powder topical formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery.
MDCO: 25.39 (-0.19)
Medicines Co. prevails in patent challenge from Mylan
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 8:43AM CDT
MDCO: 25.39 (-0.19), MYL: 53.32 (-1.39)
Alnylam and The Medicines Company Announce Filing of a Clinical Trial Application to Initiate a Phase 1 Study for ALN-PCSsc, an Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
Business Wire - Tue Oct 28, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on the world's leading acute/intensive care hospitals, announced today that Alnylam has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia. ALN-PCSsc is a subcutaneously administered RNAi therapeutic targeting the gene proprotein convertase subtilisin/kexin type 9 (PCSK9), a target validated by human genetics that is involved in the metabolism of low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Per the filed CTA, the Phase 1 trial of ALN-PCSsc will be conducted in the U.K. as a randomized, single-blind, placebo-controlled, single ascending- and multi-dose study, enrolling up to 76 volunteer subjects with elevated baseline LDL-C (greater-than or equal to 100 mg/dL). Following approval of the CTA, the companies expect to initiate dosing in the Phase 1 trial in late 2014 or early 2015, with initial data expected to be reported in mid-2015.
ALNY: 100.45 (+0.23), MDCO: 25.39 (-0.19)
